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Abstract: Dengue fever and dengue haemorrhagic fever (DHF) with shock syndrome are
found in tropical and subtropical areas of Asia, Africa, Western Pacific and Central and South
America. DHF is one of the major causes of hospitalization of children in urban of these
areas. Control of the mosquito is the only means available now to curb the disease.
Therefore a vaccine is urgently needed. Sequential infections with different dengue virus
serotypes represent a risk factor for DHF. Prior immunity to a heterologus serotype enhance
virus infection of another serotype in macrophages and monocytes. Thus, the approach of
the Steering Committee (SC) of W. H. O. is to develop a tetravalent candidate vaccine
including 4 serotype antigens or to engineer dengue vaccines without the component of
immune-mediated enhancement.
The strategic plan of the SC had included (a) definition of protective epitopes; (b)
expression of protective epitopes; (c) definition of virulence in molecular terms. In view of
the fruits, the following strategic plans of the SC were included. i. Infectious clone research
using parental and candidate vaccine strains and definition of virulence and attenuation in
molecular terms. ii. Construction and expression of protective immunogens by genetic
engineering techniques. iii. Development of animal model for DHF. iv. Development of
candidate vaccines.
Flaviviruses and their vectors are nowspread over a very large area of the world.
Dengue is a mosquito-borne disease which occurs in almost all tropical countries including
somesubtropical areas. Dengue is the most serious and rapidly rising arbovirus infections
in the world. The best estimation is that millions of DHF cases occur each year, with
thousands of deaths, but this is probably an underestimate. The number of dengue
epidemics has substantially increased in the past 10 years. The table 1 shows countries or
territories in which dengue or DHF is known to occur, in 1975-1993 by W. H. 0. One fifth
of the world's population is at risk of dengue in these areas. Dengue nowcauses massive
epidemics in non-immunepopulation and income loss incurred during dengue and DHF
epidemics is a major economic problem in these countries. The recent increase in dengue
transmission has resulted mainly from rapid urbanization in endemic countries. Although
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T able 1. Countries or territories in which dengue or dengue haemorrhagic fever is known to occur, by W.
H. 0. region, 1975-1993
The Americas (40) A ntigua, Aruba, Bahamas, Barbados, Belize, Bolivia, Bonaire, Brazil,
British Virgin Islands, Curaqao, Colombia, Cuba, Dominica, Dominican
Republic, Ecuador, El Salvador, French Guiana, Grenada, Guadeloupe,
Guatemala, Guyana, Haiti, Honduras, Jamaica, Martinique, Mexico, Mont-
serrat, Nicaragua, Paraguay, Puerto Rico, Saint Kitts and Nevis, Saint
Lucia, Saint Martin, Saint Vincent and the Grenadines, Suriname, Trinidad
and Tobago, Turks and Caicos Islands, U. S. A., Venezuela, Virgin Islands
of the U. S.,
South-East Asia (7) | Bangladesh, India, Indonesia, Maldives, Myanmar, Sri Lanka, Thailand,
W estern Pacific (26) A merican Samoa, Australia, Cambodia, China, Cook Islands, Fiji, French
Polynesia, Guam, Kiribati, Lao People's Democratic Republic, Malaysia,
Marshall Islands, Nauru, New Caledonia, New Zealand, Niue, Palau,
Philippines, Samoa, Singapore, Tokelau, Tonga, Tuvalu, Vanuatu, Viet
Nam, Wallis and Futuna Islands,
Africa (18) Burkina Faso, Comoros, Cote d'lvoire, Ethiopia, Ghana, Guinea, Kenya,
Madagascar, Mozambique, Nigeria, Senegal, Seychelles, Sierra Leone,
Somalia, South Africa, Sudan, United Republic of Tanzania, Zaire,
Europe (1) I Bosnia and Herzegovina,
E astern Mediterranean (0)
all ages suffer from dengue fever, DHF is most commonly observed in children. During
severe epidemics many of the infected infants and children can die, even if properly treated.
Control of the mosquito is the only means available now to curb the disease. Therefore
a vaccine is urgently needed.
The problem
Dengue virus is classified into 4 distinct serotypes, named dengue 1, 2, 3 and 4, and
any of the four serotype viruses cause classic dengue fever in humans. No cross-protec-
tion exists among these serotypes, and an individual who has recovered from one serotype
of dengue infection and developed antibodies against the virus remains susceptible to
infections by other dengue viruses. While it is generally a debilitating but non-fatal illness
so called classical dengue fever, a proportion of infected patients experience a more severe
form of the disease called DHF which is often complicated by shock. Unfortunately, a
second infection with a different serotype of dengue virus has been associated with an
enhanced risk of developing DHF and death(Table 2). For this reason, dengue vaccines
cannot be fielded one at a time as they become available : it appears essential that an
235
i mmunization program against dengue should provide simultaneous protection against all
four serotypes. The precise mechanism of developing DHF is not clear and an efficacy
test for a candidate vaccine cannot be done on DHF now,because an animal model for
DHF is still lacking, however several hypothesis have been postulated.
The immuneenhancing or antibody dependent enhancing phenomena of virus infec-
tions have been observed in vitro not only on dengue virus but also on other viruses.
Dengue virus can infect adherent human monocytes. Whenthe dengue virus is mixed and
formed immunecomplexes with cross-reactive antibodies, infectivity of the dengue virus
is greatly enhanced. The concept that dengue viruses can infect human monocytes more
easily as an immunecomplex with non-neutralizing antibodies via a Fc receptor on the cell
surface for immunoglobulines than as individual virion via a cellular receptor for dengue
virus have been accepted to explain the antibody dependent enhancement of dengue virus
infectivity in vitro (Table 3). Similar phenomena were also observed on other virus
infection. On Japanese encephalitis virus (JEV) infection, pre-existence of certain non-
neutralizing monoclonal antibodies against JEV induced earlier death on the mice infected
T able 2. Dengue virus and its disease





Dengue haemorrhagic fever (DHF)
Dengue shock syndrome (DSS)
DHF/DSS occurs at relatively high frequency in infants and
chi ldren
DHF/DSS occurs at relatively high frequency during secondary
dengue infections
T able 3.
Antibody-dependent enhancement of dengue virus infectivity
Dengue virus can infect human monocyte more easily as an
immune complex with non-neutralizing antibodies via a Fc
receptor for immunoglobulin than as an individual virion via a
cellular receptor for dengue virus
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with JEV. As shown figure 1, mice received non-neutralizing monoclonal antibody 201 or
302 passively 1 day before JEV inoculation died earlier than mice received normal mouse
IgG, however mice received neutralizing antibody 503 were completely protected from JEV
infection (Figure 1). It is not clear whether antibody dependent enhancement of dengue
virus infectivity is first step for development of DHF in vivo. However, because DHF and
dengue shock syndrome (DSS) occurs at relatively high frequency during secondary dengue
infections and in infants less than 1 year old, a candidate vaccine and its immunization
program for dengue should induce simultaneous good protection against all four serotype
viruses.
Targeted research activities and strategic plan
JEV is a close biophysical relative of the dengue viruses and can cause severe disease
throughout much of Asia. At least 40,000 cases of JE is estimated in each year, of which
one third will die and one third will suffer very serious long-term effects. Although
inactivated vaccine made from homogenized, infected mouse brain or using primary
hamster kidney cells is used by a number of countries, an inexpensive, single inoculation
vaccine that induces long-lasting immunity is needed. So W, H.0. also support the
development of new JEV vaccine using new biotechnology as same as dengue vaccine.
The development of inactivated dengue vaccines has not been previously achieved
because these viruses do not grow to high enough yields in cell culture to produce sufficient












Fig. 1. Earlier death of JEV-infected mice by passive administration with certain mAb. The
mice were administered i. p. with 200 /^/mouse of each rnAb 1 day before JEV inocula-
tion. Symbols: O, control (normal mouse IgG): à", mAb 201; A, mAb 302; A, mAb
109 ; D, mAb 503 ; Similar results were obtained from two or more independent observa-
tions.
237
antigen for successful immunization. After many efforts, live attenuated candidate vac-
cines have been developed at Mahidol University, Thailand and at the Walter Reed Army
Institute of Research, U. S. A. The tetravalent dengue candidate vaccines developed at
Mahidol University are nowtried on phase 1 and 2 test in Thailand with support of W. H.
O./SEARO, as reported by Dr. Natth Bahamarapravati, but second generation vaccine will
also be needed.
The strategic plan of the Steering Committee on Dengue and Japanese Encephalitis
Vaccine, elaborated in 1987, is shown in Table 4. The main aims is to produce second
generation vaccines by using these approaches and its time frame is shown in Figure 2.
The initial aims have been accomplished to a large extent on several parts. Protective
Table 4.
( a) Identification of critical (protective, neutralizing and enhancing) epitopes.
(1) Human sera targets (viral protein exposure)
(2) Mouse monoclonal antibody production and characterization
(3) Active mouse immunization (with isolated viral proteins)
(4) Passive mouse immunization (with monoclonal antibodies)
(b) Expression of critical (protective/neutralizing) epitopes.
(1) CDNA cloning and sequencing
(2) Expression and/or synthesis of viral proteins and/or peptides
(3) Immunization experiments
(4) Challenge experiments
(c) Optimization of immunization.
(1) Adjuvants/immuno-enhancers
(2) Expression systems (E. coli, yeast etc.)
(3) Self-replicating vectors (yellow fever, vaccinia etc.)
(d) Molecular definition of virulence.
(1) Cloning, sequencing and comparison of parent versus vaccine strain pairs
(2) Cloning, sequencing and comparison of "classical" dengue versus dengue haemorrhagic fever
strain pairs
(e) Construction of engineered live attenuated vaccines.
(f) Similar lines of research will be supported on JE.
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epitopes on E proteins were identified. NS1 protein was also shown to confer protection,
although not inducing neutralizing antibodies. Expression of the E and other proteins was
successfully accomplished in E. coli, vaccinia virus and baculovirus systems and other
expression systems of the E protein in mammalian cells have been developed. The genetic
basis for virulence was studied by examining sequences in parent and candidate live
attenuated vaccine pairs. Infectious clones of yellow fever, dengue 4 and JEV have now
been made. Infectious clones and chimeric viruses may be one of possible candidate
vaccines. Purified subunit truncated E protein is reportedly immunogenic and can be
produced in baculovirus systems(Table 5). Recombinant vaccinia viruses, baculoviruses,
and other expression vectors produce small immunogenic particles including E and M
proteins of JEV and these particles elicit neutralizing antibodies and protect mice from the
challenge by JEV and prevent the viremia in pigs. Studies with vaccinia recombinant
viruses in human subjects are in the planning stage. Briefly, when preM and E coding
region genes are exressed by vaccinia virus, baculovirus or mammalian cell expression
systems, E and preM proteins are produced in cells as E-preM heterodimer. And these
proteins are released from the cells to culture supernatant as about a 20 nm envelope
particle containing E and processed M proteins as E-M associating complex. The E-M
associating complex expresses biologically active epitopes well, but E alone does not. And
E-Menvelope particle can elicit protective immunity in animals excellently (Table 6).
These appoach is now being extended for dengue viruses. From these progress, the SC
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Fig. 2. WHO strategy to develop the Second generation dengue vaccine
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modified the priorities of research for development of the second generation vaccine as
shown in Table 7.
The SC recommended following project for funding 1993.
Renewal projects
BLAIR (USA) : Identification of dengue 1 virus genome sequences that mediate antiboby
-enhancement of dengue-2 viruses.




vaccinia, rubella, adeno, Semliki Forest, Salmonella, BCG,
S ubunit including NS antigens
baculo, peptide, purified proteins, bacteria cells,
P article
vaccinia, baculo, mammalian cells, liposome, ISCOM,
I mmunology
epitope mapping, structure of the antigens, T cell, ADE, Receptor, targer (Dendric
cell) cells,
Table 6. Expression of flavivirus E envelope particles and development of protective
immunity in animals with the particles
ss preM-E coding region of flavivirus genome
vaccinia virus, baculovirus, and other animal cell expression systems
expressed extracellular E envelope particles or cell surface E
good expression of biologically active epitopes and excellent immunogens to elicit
protective immunity in animals.
ca 20nm particles which contain E and M protein.
chimera particles with different flavivirus E proteins are available.
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Table 7. Research priority of WHO dengue vaccine development
( a) Infectious clone studies using existing parental and candidate vaccine strains.
These studies will include elucidation of the molecular definition of virulence
and attenuation.
(b) Studies which utilize available data on protective antigenic sites to construct
and express protective immunogens.
Approaches envisioned would include recombinant DNA generated particles or
antigens vectored by currently available delivery methods, and chimeric parti-
cles or viruses.
(c) Research evaluating, comparing, and then optimizing the protective efficacy of
these antigens in current or newly developed animal model systems.
(d) Projects aimed at the development of vaccine candidates including methodologic
research on production, purification and process development, and manufacture
of pilot lots under Good Manufacturing Practice (GMP) guidelines.
CALLER (Brazil) : Molecular analysis of yellow fever vaccine viruses
SHOPE (USA) : Production and evaluation of vaccinia vectored dengue virus vaccines
SHOPE (USA) : Engineering an attenuated strain of Japanese encephalitis virus for use as
a humanvaccine
STRAUSS (USA) : Expression of flavivirus proteins
Newprojects
DEUBEL (France) : Expression, purification and evaluation of the protective efficacy of
the four serotypes of dengue E protein fused to MalE
SUMIYOSHI (USA) : Development of an infectious CDNAclone for dengue type 3 virus
YOUNG (Australia) : Baculovirus expressed immunogenic particles as candidate sub-unit
dengue virus vaccine
BRINTON (USA) : Molecular analysis of dengue virus-specific, human cytotxic T-cell
immunodominant epitopes
COMPANS (USA) : Virus-like particles as dengue vaccine
The 1993 World Health Assembly in a resolution has noted the worldwide importance
of dengue haemorrhagic fever as an increasing disease problem. The resolution called for
vaccine development in addition to better diagnostic and control of the vectors. Because
there are severe restrictions in funding of W. H. 0. for coming year clear programme focus
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is essential in order to achieve the SC goal of efficacious, safe, inexpensive vaccine for
dengue and JEV in the near future.
This paper was written according to W. H. 0. SC reports.
